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Background: There is increasing evidence on complex interaction between the nervous and immune systems in
patients with cerebral infarction. This study was conducted to evaluate cytotoxic function of CD8+ T lymphocytes
isolated from patients with acute severe cerebral infarction. In order to determine role of immune system in stroke,
peripheral blood mononuclear cells (PBMCs) were taken and cytotoxic function of CD8+ T lymphocytes were
induced by virus peptides and cells were analyzed on a four-color flow cytometer. Expression of CD107a,
intracellular expression of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), and cell proliferation assay were
analyzed by using carboxyl fluorescein diacetate succinimidyl ester (CFSE).
Results: A total of 30 patients with cerebral infarction and 30 healthy volunteers with an average age 57
(range, 49 to 71) years, were evaluated. The PBMCs were separated from blood samples of both, patients
with cerebral infarction 6 hours after onset of stroke and healthy volunteers. After stimulation with virus
peptides, CD107a expression and intracellular production of IFN-γ and TNF-α was decreased in patients with
cerebral infarction as compared to healthy volunteers (p < 0.01). Degranulation analysis reported decreased
expression of CD107a + in patient group as compared to healthy group, p <0.01. A mild decrease in
intracellular expression of IFN-γ and TNF-α was also shown in patients without stimulation of virus peptides
(p < 0.05). However, proliferation of CD8+ T lymphocytes in patients with acute severe cerebral infarction
was not decreased.
Conclusions: The study results indicated that cytotoxic function of CD8+ T lymphocytes were suppressed in
patients with acute severe cerebral infarction. This could possibly be associated with complicated infectious
diseases and neuroprotective mechanism.
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Cerebral infarction, a cerebrovascular disease, is the most
frequent disease of the brain and the leading cause of mor-
tality worldwide. Cerebral infarction is an ischemic stroke
resulting in cell death due to lack of blood supply to the
brain. Complications after ischemic stroke are common
and related to poor prognosis [1]. Infection is the most* Correspondence: xinwang021@yahoo.cn
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reproduction in any medium, provided the orfrequently occurring complication in patients with acute
cerebral infarction and is difficult to control [2,3]. Numer-
ous immunohematologic abnormalities have been reported
with infection-associated cerebral infarction [4].
The immune system is responsible for protection
against infectious diseases. Some studies have confirmed
that patients with alterations in immune function are at
increased risk of infection or decreased immunity [4-6].
The CD8+ T lymphocytes (cells) and natural killer (NK)
cells are components of the adaptive immunity and innate
immunity, respectively and constitute cellular immunityhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cells than CD8+ T lymphocytes. It has also been reported
that adaptive immunity was inferior to innate immunity in
exerting the cytotoxic effect. However, recent immuno-
logical researches support the role of CD8+ T lymphocytes
for the elimination of infectious pathogens from the body
[7,8]. This effect against pathogens is exerted by secreting
cytokines like interleukins (ILs), interferon-γ (IFN-γ), and
tumor necrosis factor-α (TNF-α). The cytotoxic responses
have shown beneficial effects in controlling various infec-
tions and tumors [7].
The incidence of infection as the most common com-
plication as well leading cause of death is on the rise in
patients with stroke [3,6]. Suppression of immune sys-
tem after cerebral infarction increases susceptibility to
infections and significantly affects survival of patients
after stroke. Ischemic stroke involves both innate and
adaptive immunity. However, adaptive immunity has no
impact in the acute stage of stroke, but modulation of
adaptive immunity can exert a protective effect [9].
The objective of the present study was to assess the
changes in immune function after stroke and to analyze
cytotoxic function of CD8+ T lymphocytes in peripheral
blood of patients with acute severe cerebral infarction.
Methods
Patient selection
This study was conducted from January 2009 to
January 2011. Patients with clinical evidence of acute
severe cerebral infarction were eligible for enrolment
in the study (n=30). Other inclusion criteria were age
40 – 80 years, radiographic evidence of acute cere-
bral infarction, patients hospitalized within 6 hours
after the onset of stroke, a score of not less than 16
as per the National Institutes of Health Stroke Scale
(NIHSS) on admission. The exclusion criteria were: if
the onset was along with infectious and autoimmune
diseases, patients who received thrombolytic therapy
after the onset, patients receiving immune regulation
therapy within 6 months before the onset, patients
with history of cerebral stroke within 12 months be-
fore the onset, patients who had history of severe
cerebral trauma or neurosurgery, seizures during the
onset and at the time of admission, renal or hepatic
insufficiency at admission, history of blood transfu-
sion within 12 months before the onset, severe
trauma or surgery within 2 weeks before the onset,
and history of severe psychological disease. A group
of healthy adult volunteers (n=30; age: 40-80 years)
were also included in the study for comparison. All
patients or their family members provided signed
informed consent and the protocol was approved by
The Committee of Medical Ethics, East Hospital,
Tongji University.Antibodies and reagents
Only mouse anti-human antibodies (purchased from
BD Biosciences, USA) were used in the study. This
included allophycocyanin (APC) conjugated to CD3
(CD3-APC), peridinin chlorophyll protein (PerCP) con-
jugated to CD8 (CD8-PerCP), fluorescein isothiocyan-
ate (FITC) conjugated to cluster of differentiation 107a
(CD107a-FITC), and phycoerythrin (PE) conjugated to
interferon-γ (IFN-γ-PE) and tumor necrosis factor-α
(TNF-α-PE). Ficoll-Biocoll, a cell isolation liquid and
phosphate-buffered saline (PBS) were used (Biochrom
AG, Germany). Perm/Wash™ buffer was used in the
analysis to serve as an antibody diluent and cell wash buffer
(BD Biosciences, USA). Cytofix/Cytoperm™ solution (BD
Biosciences, USA) was used to increase the permeability of
cell membrane. BD GolgiStop™ (BD Biosciences, USA),
was used as a protein transport inhibitor containing mon-
ensin and was required to promote cytokine accumulation
in the Golgi complex. RPMI-1640 (Roswell Park Memorial
Institute medium, Sigma, Germany) was used as the cell
culture medium (CTM). Cells were cultured in RPMI-1640
supplemented with 20 mM HEPES ([4, (2-hydroxyethyl]-1-
piperazineethanesulfonic acid), 2 mM glutamine, 1% peni-
cillin/streptomycin (Sigma, Germany), and heat-inactivated
10% human AB serum (3H Biomedical AB, Sweden). Cell-
Trace™ carboxyl fluorescein diacetate succinimidyl ester
(CFSE) was used as a cell proliferation reagent (Invitrogen,
USA). Trypan blue solution (0.4%) was used to assess cell
proliferation and viability by dye exclusion method
(GIBCO, UK). Recombinant human interleukin-2 (rhIL-2)
was purchased from ProSpec (Rehovot, Israel) and CD28/
CD49d costimulatory antibody from BD Biosciences
(USA). Mixed virus peptide used in the study was CTL-
CEF-Class I peptide pool “Plus” (CEF peptide) (Cell Tech-
nology Ltd, USA). CEF peptide was a pool of 32 peptides,
with sequences derived from the human cytomegalovirus,
Epstein-Barr virus, and influenza (flu) virus.Isolation of peripheral blood mononuclear cells
PBMCs were isolated from whole blood as the red cells
could have interfered with the flow cytometer analysis.
In our preliminary experiments, we observed the apop-
totic ratio of isolated PBMCs with Ficoll-Biocoll method
and with lysate method (data not shown). Annexin V
Apoptosis Detection Kit was used to detect apoptosis.
The viability of PBMCs obtained was always > 95% with
Ficoll-Biocoll method and < 50% with Lysate method.
Hence, Ficoll separation method was used in the study.
Peripheral venous blood (20 ml) samples were col-
lected from patients with cerebral infarction 6 hours
after the onset of stroke in a heparinized test tube. The
entire blood sample was diluted to a final volume of
20 ml with PBS. This suspension was then poured into
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After density gradient centrifugation (1500 rpm, 20°C,
30 minutes, without brake), peripheral blood mono-
nuclear cells (PBMCs) were isolated. The isolated cells
were collected carefully and washed with sterile PBS and
re-suspended in RPMI-1640. Cell viability was deter-
mined by trypan blue staining and cells were counted;
cell viability should always be > 95%. Final density of the
cell in CTM was adjusted to 5-6 × 106 cells/ml. PBMCs
from healthy volunteers were isolated in the same way.
Collection of blood from the patient population and
healthy volunteers was carried out at Philipps-University
Marburg, Germany.
CD107a degranulation analysis
For the expression of CD107a, 20 μl of CD107a-FITC
antibody was added into 80 μl of PBMCs suspension
(2-3 × 106 cells/ml). PBMCs suspension mixed with
CD107a was dispensed in a flat-bottom 96-well plate.
Into each well, 2 μl of CD28/CD49d costimulatory
antibody was also added. Further, 100 μl of CEF pep-
tides with concentrations of 64 μg/ml were added in
the CEF-treated-control group, and the same amount
of CTM in the negative control group. The culture
was incubated for 60 minutes at 37°C in 5% CO2 in-
cubator after which 0.5 μl BD GolgiStop containing
monensin was added. The incubation was continued
for 120 minutes. After washing, cells were stained
with CD3-APC and CD8-PreCP antibodies and incu-
bated for 30 minutes at 4°C in the dark. Cells were
centrifuged, supernatant was discarded and resus-
pended in 130 μl of CTM. Cells were analyzed on the
four-color flow cytometer (FACSCaliburW, CellQuestW
software, Becton Dickinson). At least 50000 events
(events refer to the number of particles recorded by
flow cytometry) were collected per cell. In the
lymphocyte gate, CD8+ T lymphocyte for CD107a ex-
pression was defined as CD3+/CD8+/CD107a.
Intracellular IFN-γ and TNF-α analysis
For analysis of intracellular IFN-γ and TNF-α, 2 μl
CD28/CD49d costimulatory antibody was added to
100 μl of PBMCs. This suspension was dispensed into
flat-bottom 96-well plate. Further, 100 μl of CEF pep-
tides with concentration of 64 μg/ml was added in the
CEF-treated-control group, and the same amount of
CTM in the negative control group. The culture was
incubated for 60 minutes at 37°C in 5% CO2 incubator
and 0.5 μl BD GolgiStop containing monensin was
added. This was further added at an interval of 6 hours
during the next 24-hour incubation. Cells were centri-
fuged and supernatant was discarded. After washing,
cells were stained with CD3-APC and CD8-PerCP anti-
bodies, and incubated at 4°C for 30 minutes in the dark.Cells were then fixed with the 100 μl of BD Cytofix/
Cytoperm solution and incubated for 20 minutes at 4°C in
the dark. After washing and centrifugation, cells were sus-
pended in Perm/Wash buffer solution and 20 μl of IFN-γ-
PE and 20 μl of TNF-α-PE antibodies were added and
incubated for 30 minutes at 4°C in the dark. Cells were
analyzed on the four-color cytometer (FACSCaliburW,
CellQuestW software, Becton Dickinson). Data from at
least 50000 events per cell were acquired. In the lympho-
cyte gate, IFN-γ positive CD8+ T lymphocyte was defined
as CD3+/CD8+/IFN-γ + and TNF-α positive CD8+ T
lymphocyte was defined as CD3+/CD8+/TNF-α + .
Cell proliferation analysis
CFSE stock solution was prepared and added into PBMCs
in culture media. The working concentration of CFSE used
was 0.4 μM. The culture media was incubated in the dark
for 10 minutes at 37°C. The freed CFSE was inactivated with
ice on CTM. It was again centrifuged and washed and cells
were resuspended in CTM. The cell density was set at 2-3 ×
106 cells/ml. Cell suspension (stained with CFSE) was then
dispensed into a flat-bottom 96-well plate. In cell suspen-
sion, 2 μl of CD28/CD49d costimulatory antibody was
added. Then 100 μl of CEF peptides with concentration of
64 μg/ml and rhIL-2 with final concentration of 40 IU/ml
was added in the CEF-treated-control group, and the
same amount of CTM was added in the negative
control group. After 5 days of incubation at 37°C in
5% CO2 incubator, cells were centrifuged, supernatant
was eliminated and CD3-APC and CD8PerCP anti-
bodies were added and incubated for 30 minutes at 4°C
in the dark. Cells were again centrifuged, supernatant
was discarded, washing was repeated, and cells were
resuspended in 130 μl of CTM. Cells were analyzed on
the four-color flow cytometer (FACSCaliburW, Cell-
QuestW software, Becton Dickinson). At least 50000
events were collected per cell. The percentage of prolif-
erating cells was measured by the percentage of low
CFSE cells in CD3+/CD8+ gate (in the upper left quadrant
of each plot). The definition for low CFSE cells was defined
according to the distribution of CFSE dye in baseline,
which was measured in unstimulated cells. CFSE decrease
was a result of dye dilution in each cell division.
Statistical analysis
All values were expressed as mean ± standard deviation
(SD). Continuous data were analyzed using the paired
t-test. For statistical comparisons, a p value less than
0.05 was considered to be significant.
Results
Patient characteristics
The study included 30 patients (17 males and 13
females) with acute severe cerebral infarction and 30
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mean (SD) age of the patients with cerebral infarction and
the healthy volunteers was 56.9 ± 13.5 (range: 50 to 69)
years and 57.1 ± 14.5 (range: 49 to 71) years, respectively.
There was no significant difference between both groups
for demographic characteristics such as age, gender and
weight (Table 1).Changes in immune function
Results from CD107a degranulation, CFSE cell proliferation
and intracellular IFN-γ and TNF-α analysis for patients with
cerebral infarction and healthy volunteers are shown in
Table 2. Statistical analysis shows that after stimulation of
CD8+ T lymphocyte by CEF peptide, there were significant
differences between the two groups (p < 0.01) for both
CD107a expression on the cell surface and intracellular ex-
pression of IFN-γ and TNF-α. After activation of CD8+ T
lymphocyte, expression of CD107a and production of pro-
inflammatory cytokines in patients with cerebral infarction
was decreased compared to healthy volunteers. However,
there was no statistical difference in the degree of cell pro-
liferation between the two groups (p > 0.05).
Comparing the negative control groups (it refers to the
healthy volunteer group not stimulated by CEF peptide), it
was found that the content of intracellular pro-
inflammatory cytokines of CD8+ T lymphocyte in patients
with cerebral infarction was lower as compared to healthy
volunteers (p < 0.05). No other differences were found.
The expression of CD107a, intracellular expression of
IFN-γ and TNF-α, and cell proliferation between patient
and healthy volunteer groups were assessed by CFSE
(Figure 1). Cytokine expression (IFN-γ and TNF-α) and
CD107a expression was significantly decreased in the
patient group as compared to the healthy volunteer
group, p <0.01.Degranulation analysis
Degranulation analysis of CD8+ T lymphocytes was per-
formed to check for the expression of CD107a on the cell
surface. Degranulation analysis conducted by comparing
the percentage of CD107a + expression in patients with in-
farction and healthy volunteers is presented in Figure 2.
After 3-hour stimulation of CD8+ T lymphocytes by CEF
peptide in vitro, it was found that there was a decreasedTable 1 The demographics data of cerebral infarction




group (N = 30)
p value
Male: female 17:13 17:13 >0.05
Age, y (mean) 56.9 (50-69) 57.1 (49-71) >0.05
Weight, kg (mean) 77 (65-90) 75 (63-90) >0.05expression of CD107a + in patients as compared to healthy
volunteers, p < 0.01.
Intracellular expression of IFN-γ and TNF-α
Contrasting images for intracellular expression of IFN-γ
and TNF-α in cerebral infarction patients and healthy
volunteers after 24-hour stimulation of CD8+ T lympho-
cytes by CEF peptide in vitro is shown in (Figure 3).
Flow cytometry analysis revealed decline in concentra-
tion of IFN-γ and TNF-α in the patient group as com-
pared to the healthy volunteer group.
Cell proliferation analysis
Data for the percentage of proliferating cells after 5-day
stimulation of CD8+ T lymphocytes by CEF peptide
in vitro have been reported. There was no significant dif-
ference in the percentage of proliferating cells between
patients with cerebral infarction and healthy volunteers
on flow cytometry analysis.
Discussion
Infection is considered as the cause as well as compli-
cation of stroke in patients with cerebral infarction.
The incidence rate of infection in the acute stage of
cerebral infarction is about 16% to 27% [2,3], this fre-
quency rises in severe cases of infarction. This indi-
cates the possibility of dysfunction of immune system.
However, limited data is available on the function of
CD8+ T lymphocytes. Our study found that the cyto-
toxic function of CD8+ T lymphocytes in the peripheral
blood of patients with severe cerebral infarction was
suppressed. This resulted in decrease rate of degranu-
lated cells and pro-inflammatory cytokine production
after stimulation by mixed virus peptides in vitro. How-
ever, cell proliferation was not affected. Before stimula-
tion of CD8+ T cells with CEF peptides, there was a
small difference (p < 0.05) between patients with cere-
bral infarction and healthy volunteers for intracellular
pro-inflammatory cytokines of CD8+ T lymphocytes.
One possibility was that severe stroke might possibly
induce mild release of IFN-γand TNF-α from CD8+
lymphocytes, needs further investigation.
A study by Peterfalvi et al, reported that pro-inflammatory
and cytotoxic responses of NK, NKT-like and Vdelta2 T
cells become acutely deficient in ischemic stroke, which may
contribute to an increased susceptibility to infections [10].
BD GolgiStop containing monensin was used in the
current study with the objective to prevent the degrad-
ation of fluorescence on CD107a antibody and also to
inhibit the transposition of intracellular cytokine from
golgi body to the outside to limit the effect induced by
cytokine release [11].
The CD8+ T lymphocytes are considered as the key ef-
fector cells in the adaptive immune response. The cytotoxic
Table 2 Parameters of cytotoxicity of CD8+ T lymphocytes in cerebral infarction patient group and healthy volunteer
group with or without stimulation by virus peptides
Cerebral infarction patient group Healthy volunteer group
Not stimulated Stimulated Not stimulated Stimulated
CD107a + (%) 0.9 ± 0.6 10.6 ± 3.7** 0.8 ± 0.4 15.6 ± 4.3
IFN-γ + (%) 3.0 ± 1.2 * 15.3 ± 4.3** 3.6 ± 1.7 20.0 ± 5.1
TNF-α + (%) 3.3 ± 1.4* 15.1 ± 4.4** 4.1 ± 2.1 19.3 ± 4.7
Low CFSE (%) 0.7 ± 0.6 9.0 ± 3.5 0.9 ± 0.5 10.1 ± 4.0
All values are mean ± SD; ** p < 0.01, *p < 0.05, comparing between cerebral infarction patient group and healthy volunteer group. CD107a: cluster of
differentiation 107a; CFSE Carboxyl fluorescein diacetate succinimidyl ester, IFN Interferon, TNF tumor necrosis factor.
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and non-degranulation [12-14]. The former means that the
cells will release cytotoxins containing perforin and various
granzyme after activation, which results in direct paralysis of
the target cell or apoptosis. However, the later indicates that
the apoptosis of the target cell is induced through the pro-
duction and release of cytokines such as IFN-γ and TNF-αFigure 1 Comparison of expression of CD107a, IFN-γ and TNF-α and C
Expression of CD107a, IFN-γ and TNF-α, and CFSE dilution degree after CD8
in vitro at different time points (CD107a: 3 h; IFN-γ and TNF-α: 24 h; CFSE d
used for analysis; ** p < 0.01; *p < 0.05. CD107a: cluster of differentiation 10
Interferon; TNF: tumor necrosis factor.[15]. Our study revealed that compared to healthy volun-
teers, the two pathways mentioned above were probably
suppressed in patients with severe acute cerebral infarction,
resulting in inhibition of cytotoxic function.
Cell proliferation is mainly responsible to enlarge the
cytotoxic effects of CD8+ T lymphocytes, but the prolif-
eration of CD8+ T lymphocytes in patients with cerebralFSE dilution degree between patients and healthy group.
+ T lymphocytes stimulated and not stimulated by CEF peptide
ilution degree: 5d). Data is presented as mean ± SD. One-tailed t-test is
7a; CFSE: carboxyl fluorescein diacetate succinimidyl ester; IFN:
Figure 2 Comparison of CD107a expression in patients with cerebral infarction and healthy volunteers with and without stimulation
with CEF peptide. Expression of CD107a between the two groups stimulated and not stimulated by CEF peptide in vitro. A is the contrast of
cerebral infarction patient without stimulation; B, the comparison of healthy volunteer without stimulation; C shows the increase of CD107a +
cells in cerebral infarction patients after stimulation with CEF peptide for 3 h; and D shows the increase of CD107a + cells in healthy volunteers
after stimulation with CEF peptide for 3 h. CD107a: cluster of differentiation 107a.
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turing of cells has major differences from those in vivo
(as in patients with cerebral infarction), especially in
terms of the cell conditions and time of proliferation.
The suppression of the cytotoxic function of CD8+
T lymphocytes in patients with severe cerebral in-
farction lowers the patient’s resistance to infection,
but it may also have some protective effect. Recent
animal studies have proven that CD8+ T lymphocytes
induce neurotoxic effects in the early stage of acute
cerebral ischemia. In a study with gene knock-out of
CD8 + T lymphocytes by Yilmaz et al., the size of
cerebral infarction in mice was distinctly reduced
[16]. Therefore, the cytotoxic function of CD8+ T
lymphocytes may be attributed to a self-protective
mechanism [17].
In the current study, it was observed that without
stimulation, patients with cerebral infarction had mild de-
cline in intracellular pro-inflammatory cytokines of CD8+
T lymphocytes than the healthy volunteers. This indicatedFigure 3 Comparison of intracellular expression of IFN-γ and TNF-α in
stimulation with CEF peptide for 24 h in vitro. A is the IFN-γ expression
infarction patient; C shows the IFN-γ expression of healthy volunteer; and Dthat severe cerebral infarction itself mildly induced CD8+
T lymphocytes to release IFN-γ and TNF-α. Further re-
search in this area will elucidate the role of CD8+ T lym-
phocytes. It is worth noting that an accumulating body of
evidence from experimental studies support a definite
neurotoxic role of CD8+ T lymphocytes [16-18]. So, inhi-
biting the cytotoxic function of CD8+ T lymphocytes in
acute severe cerebral infarction was a mechanism of self-
neuroprotection. From a clinical viewpoint, the balance be-
tween activating and inhibiting the cytotoxic function of
CD8+ T lymphocytes requires further investigation.
Conclusions
Findings from our study show that the cytotoxic func-
tion of CD8+ T lymphocytes in patients with acute se-
vere cerebral infarction was suppressed. These results
will help in identifying the reasons of high infection rate
and the difficulty in controlling the infection in patients
with cerebral infarction. This may be attributed to the
mechanism of self-neuroprotection.patients with cerebral infarction and healthy volunteers after
of cerebral infarction patient; B, the TNF-α expression of cerebral
shows TNF-α expression of healthy volunteer.
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